Association between response to primary treatments and MGMT status in glioblastoma

Expert Review of Anticancer Therapy

Volumn 8, Issue 11, 2008, Pages 1781-1786

  Franceschi, Enrico ^a   Tosoni, Alicia ^b   Pozzati, Eugenio ^b   Brandes, Alba A ^b  

^a Azienda USL di Bologna   (Italy)

^b BELLARIA HOSPITAL   (Italy)

Author keywords

Glioblastoma; MGMT; Radiotherapy; Temozolomide

Indexed keywords

6 O BENZYLGUANIDINE; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; CARMUSTINE; CILENGITIDE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; NITROSOUREA DERIVATIVE; PROCARBAZINE; TEMOZOLOMIDE; TEMSIROLIMUS; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR;

ADJUVANT THERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE COURSE; DNA METHYLATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; ENZYME ASSAY; EPIGENETICS; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; OVERALL SURVIVAL; PROMOTER REGION; PROTEIN EXPRESSION; REVIEW; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE;

ANIMALS; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; GLIOBLASTOMA; HUMANS; TUMOR SUPPRESSOR PROTEINS;

EID: 60849114055     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.8.11.1781     Document Type: Review

References (43)

1. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med. 349(21), 2042-2054 (2003).
2. Das PM, Singal R. DNA methylation and cancer. J. Clin. Oncol. 22(22), 1 4632-4642(2004).
3. Ramsahoye BH, Biniszkiewicz D, Lyko F, Clark V, Bird AP, Jaenisch R. Non-CpG methylation is prevalent in embryonic stem cells and may be mediated by DNA methyltransferase 3a. Proc. NatlAcad. Sci. USA, 97(10), 5237-5242 (2000).
4. Fanelli M, Caprodossi S, Ricci-Vitiani L et a. Loss of pericentromeric DNA methylation pattern in human glioblastoma is associated with altered DNA methyltransferases expression and involves the stem cell compartment. Oncogene 27(3), 358-365 (2008).
5. Cadieux B, Ching TT, VandenBerg SR, Costello JF. Genome-wide hypomethylation in human glioblastomas associated with specific copy number alteration, methylenctetrahydrofolate reductase allele status, and increased proliferation. Cancer Res. 66(17), 8469-8476 (2006).
6. Uhlmann K, Rohde K, Zeller C et al. Distinct methylation profiles of glioma subtypes. Int. J. Cancer 106(1), 52-59 (2003).
7. Singal R, Ginder GD. DNA methylation. Blood 93(12), 4059-4070 (1999).
8. Strathdee G, Brown R. Aberrant DNA methylation in cancer: potential clinical interventions. Expert Rev. Mol. Med. 4(4), 1-17 (2002).
9. Garcia-Manero G, Daniel J, Smith TL et al. DNA methylation of multiple promoter-associated CpG islands in adult acute lymphocytic leukemia. Clin. Cancer Res. 8(7), 2217-2224 (2002).
10. Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res. 61(8), 3225-3229 (2001).
11. Esteller M, Garcia-Foncillas J, Andion E et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N. Engl. J. Med. 343(19),1350-1354 (2000).
12. Ludlum DB. DNA alkylation by the haloethylnitrosoureas: nature of modifications produced and their enzymatic repair or removal. Mutat. Res. 233(1-2), 117-126 (1990).
13. 6-alkylguanine-DNA alkyltransferase. Prog. Nucleic Acid Res Mol Biol. 51, 167-223 (1995).
14. 6-methylguanine-DNA methyltransferase activity in brain tumors and adjacent normal brain. Cancer Res. 53(14), 3416-3420 (1993).
15. 6-methylguanine-DNA methyltransferase activity in adult gliomas: relation to patient and tumor characteristics. Cancer Res., 58(5), 1068-1073 (1998).
16. 6-methylguanine-DNA methyltransferase-deficient phenotype in human gliomas: frequency and time to tumor progression after alkylating agent-based chemotherapy. Clin. Cancer Res. 5(4), 807-814 (1999).
17. 6-methylguanine-DNA methyltransferase. Cancer Chemother. Pharmacol. 37(6), 547-555 (1996).
18. 6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patienis treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study. J. Clin. Oncol. 16(10), 3310-3315 (1998).
19. 6-methyiguanine-DNA methyltransferase gene. Cancer Res. 57(17), 3672-3677 (1997).
20. 6-methylguanine DNA methyltransferase (MGMT) CpG island is associated with heterochromatinization of the MGMT transcription start site and silencing of the gene. Mol. Cell. Biol. 17(9), 5612-5619 (1997).
21. 6-methylguanine-DNA methyltransferase promoter region as a marker of gene silencing. Mol. Carcinog. 24(2), 85-89 (1999).
22. 6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. Cancer Res. 60(9), 2368-2371 (2000).
23. Beier D, Rohrl S, Pillai DR et al. Temozolomide preferentially depletes cancer stem cells in glioblastoma. Cancer Res. 68(14), 5706-5715 (2008).
24. Murat A, Migliavacca E, Gorlia T et al. Stem cell-related 'self-renewal' signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. J. Clin. Oncol. 26(18), 3015-3024 (2008).
25. Hegi ME, Diserens AC, Gorlia T et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352(10), 997-1003 (2005).
26. 6-methylguanine-DNA methyltransferase gene promoter methylation in glioma. J. Mol. Diagn. 10(4), 332-337 (2008).
27. Stupp R, Hegi ME. Methylguanine methyltransferase testing in glioblastoma: when and-how? J. Clin. Oncol. 25(12), 1459-1460 (2007).
28. Grasbon-Frodl EM, Kreth FW, Ruiter M et al. Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas. Int. J. Cancer 121(11), 2458-2464 (2007).
29. 6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin. Cancer Res. 10(6), 1871-1874 (2004).
30. Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352(10), 987-996 (2005).
31. Mirimanoff R, Mason W, van den Bent M et al. Is longterm survival in glioblastoma possible? Updated results of the EORTC/NCIC Phase III randomized trial on radiotherapy (RT) and concornieant and adjuvant temozolomide versus RT alone. Int. J. Radiat. Oncol. Biol. Phys., 69(3 Suppl.), 2 (2007).
32. Brandes AA, Franceschi E, Tosoni A et al. MGMT promoter methylation atatus can. predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J. Clin. Oncol. 26(13), 2192-2197 (2008).
33. 6-alkylguanine-PNA alkyltransferase activity with protracted temozolomide schedules. Br. J Cancer 88 (7), 1004-1011 (2003).
34. Wick A, Felsberg J, Steinbach JP et al. Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J. Clin. Oncol. 25(22), 3357-3361 (2007).
35. Brandes AA, Tosoni A, Cavallo G et al. Temozalomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: Phase II study from Gruppo Italiano Cooperativo di Neuro-oncologia (GICNO). Br. J. Cancer 95(9), 1155-1160 (2006).
36. 6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J. Clin. Oncol. 26(25), 4189-4199 (2008).
37. 6-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. J. Clin. Oncol. 20(9), 2277-2283 (2002).
38. Burger PC, Dubois PJ, Schold SC Jr et al. Computerized tomographic and pathologic studies of the untreated, quiescent, and recurrent glioblastoma multiforme. J. Neurosurg. 58(2), 159-169 (1983).
39. Dooms GC, Hecht S, Brant-Zawadzki M, Berthiaume Y, Norman D, Newton TH. Brain radiation lesions: MR imaging. Radiology 158(1), 149-155 (1986).
40. Tihan T, Barletta J, Parney I, Lamborn K, Sneed PK, Chang S. Prognostic value of detecting recurrent glioblastoma multiforme in surgical specimens from patients after radiotherapy: should pathology evaluation alter treatment decisions? Hum. Pathol. 37(3), 272-282 (2006).
41. Taal W, Brandsma D, de Bruin HC et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer 113(2), 405-410 (2008).
42. Chamberlain MC, Glantz MJ, Chalmers L, Van Horn A, Sloan AE. Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. J. Neurooncol. 63(3), 535-537 (2006).
43. de Wit MC, de Bruin HG, Eijkenboom W, Sillevis Smitt PA, van den Bent MJ. Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression. Neurology 63(3), 535-537 (2004).